Free press releases distribution network?

Agency / Source: AnaSpec, Inc.

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!



AnaSpec Offers α & β-Synuclein Recombinant Proteins - AnaSpec, Eurogentec Group, is pleased to offer two recombinant proteins for use in Neurodegenerative Disease Research, α-synuclein (SNCA) and β-synuclein (SNCB)
AnaSpec Offers α & β-Synuclein Recombinant Proteins

 

PRZOOM - /newswire/ - Fremont, CA, United States, 2011/02/17 - AnaSpec, Eurogentec Group, is pleased to offer two recombinant proteins for use in Neurodegenerative Disease Research, α-synuclein (SNCA) and β-synuclein (SNCB).

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Both α-synuclein and β-synuclein are expressed and purified from E. coli. α-Synuclein is a 140-amino acid long recombinant protein (GenBank Accession # NP_000336) and β-synuclein is 134-amino acid long (GenBank Accession # NP_003076).

α-Synuclein (SNCA) and β-synuclein, along with γ-synuclein (SNCG), are members of the synuclein family of small proteins expressed primarily in neural tissue and in some tumors.1 Synuclein proteins, found only in vertebrates, possess a highly conserved N-terminal domain, with a variable number of 11-residue repeats and a less conserved C-terminal, with a preponderance of acidic residues.1 α-Synuclein is used in Parkinson’s disease (PD) research, 2 and β-synuclein has been shown to induce mild experimental autoimmune encephalomyelitis (EAE) in Lewis rats.3 These proteins can be used in applications such as ELISA, western blots and microscopy imaging.

References
1. George, JM. Genome Biol. 3, reviews 3002.1 (2002).
2. Spillantini, MG. et al. Nature 388, 839 (1997).
3. Sung, Y-H. et al. Protein Sci 15, 1162 (2006).
4. Trojanowski, JQ. & VM. Lee, Ann. N. Y. Acad. Sci. 991, 107 (2003).
5. Masliah, E., et al. Science 287, 1265 (2000).
6. Van Der, PH, et al. J. Neurosci. 20, 6021 (2000).
7. Feany, MB. & WW. Bender, Nature 404, 394(2000).
8. Weinreb, PH., et al. Biochemistry 35, 13709 (1996).
9. Rivers, RC. et al. Protein Sci 17, 887 (2008).
10. George, JM. Genome Biol 3, 3002.1 (2001).
11. Bruening, W. et al. Am Cancer Soc 88, 2154 (2000).

About AnaSpec, Eurogentec Group
AnaSpec, Eurogentec Group (anaspec.com) is a leading provider of integrated proteomics and genomics solutionsTM for worldwide life science research. AnaSpec offers expertise in peptides, detection reagents, antibodies, assay kits, oligonucleotides, and qPCRs. AnaSpec carries a broad product line of biochemicals and reagents for basic research, high-throughput screening and drug discovery. AnaSpec also provides premier custom services including peptide synthesis, antibody production, assay development and oligonucleotide synthesis. AnaSpec is certified to ISO 9001:2008.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Agency / Source: AnaSpec, Inc.

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick PRZOOM - Press & Newswire Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


AnaSpec Offers α & β-Synuclein Recombinant Proteins

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name PRZOOM - Press & Newswire and LINK as the source.
 
  For more information, please visit:
Is this your article? Activate ALL web links by Upgrading to Press Release PREMIUM Plan Now!
|
Contact: Tiffany Kao - AnaSpec.com 
510-791-9560
 
PRZOOM / PRTODAY - Newswire Today disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any AnaSpec, Inc. securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!




Read Latest Press Releases From AnaSpec, Inc. / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Press Releases:

MDxHealth and Exact Sciences Sign Collaboration Agreement
BD Advances Efforts to Combat Antimicrobial Resistance with Enhanced Diagnostic Solution Offering
First European Patients Treated with DC Bead LUMI™ Radiopaque Drug-Eluting Beads
FDA Approves Genentech’s Lucentis (Ranibizumab Injection) for Diabetic Retinopathy
Biopharmaceutical Analytical Instrumentation Market Garners Strong Opportunities from Double-digit Growth in Biosimilars Finds Frost & Sullivan
BD Completes Acquisition of Caesarea Medical Electronics
MDxHealth and Ghent University Ink Licensing and Collaboration Agreements to Develop Cancer Biomarker Visualization Technology
Ipsen Completes Acquisition of ONIVYDE® (irinotecan liposome injection) and Additional Oncology Assets from Merrimack Pharmaceuticals
FDA Grants Breakthrough Therapy Designation for Rituxan® (Rituximab) in Pemphigus Vulgaris
MDxHealth Signs Agreement with Lab21 to Make SelectMDx Liquid Biopsy Test Available in the United Kingdom

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
 
NewswireToday Celebrates 10 Years in Business
Find business coaching, life coaching, executive coaching and corporate coaching, best selling coaching books, ...



PREMIUM Members


Visit  BizJobs.com

Visit  MagLar, Inc.

Visit  La Bella Bakery Artisan Bakery Arizona







 
  ©2017 PRZOOM — Limelon Advertising, Co.
Home | About PRZOOM | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR free press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneur newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today